Genomes and Genes
Summary: Radiotherapy where cytotoxic radionuclides are linked to antibodies in order to deliver toxins directly to tumor targets. Therapy with targeted radiation rather than antibody-targeted toxins (IMMUNOTOXINS) has the advantage that adjacent tumor cells, which lack the appropriate antigenic determinants, can be destroyed by radiation cross-fire. Radioimmunotherapy is sometimes called targeted radiotherapy, but this latter term can also refer to radionuclides linked to non-immune molecules (see RADIOTHERAPY).
Publications232 found, 100 shown here
- High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer modelT M Behr
Department of Nuclear Medicine, Georg August University, Gottingen, Germany
Cancer Res 59:2635-43. 1999Recent studies suggest that radioimmunotherapy (RIT) with high-linear energy transfer (LET) radiation may have therapeutic advantages over conventional low-LET (e.g., beta-) emissions...
- Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphomaG A Wiseman
Department of Radiology, Nuclear Medicine, Mayo Clinic and Mayo Foundation, Rochester, Minn 55905, USA
Eur J Nucl Med 27:766-77. 2000..The only toxicity of note is hematologic and is not correlated to red marrow radiation absorbed dose estimates or T(1/2), reflecting that hematologic toxicity is dependent on bone marrow reserve in this heavily pretreated population...
- Using anti-VEGF McAb and magnetic nanoparticles as double-targeting vector for the radioimmunotherapy of liver cancerJing Chen
Department of Nuclear Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, No 1095, Jiefang Dadao, 430030 Wuhan, People s Republic of China
Cancer Lett 231:169-75. 2006..The results suggests that the radioimmunotherapy of intratumoral injection of 131I-Sc-7269-DMN may be safe and efficient for the treatment of liver cancer...
- Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patientsStefanie Sauer
Department of Pathology, Campus Benjamin Franklin, Charite Universitatsmedizin, Berlin, Germany
Blood 113:2265-74. 2009..In 2 relapsed Hodgkin lymphoma patients(131)I-L19SIP radioimmunotherapy induced a sustained partial response, qualifying ED-B FN as a promising target for antibody-based lymphoma ..
- Doubly radiolabeled liposomes for pretargeted radioimmunotherapyM Mougin-Degraef
Département de Recherche en Cancérologie, INSERM, U601, Universite de Nantes, 9 quai Moncousu 44093, Nantes Cedex 1, France
Int J Pharm 344:110-7. 2007The aim of this study was to design liposomes as radioactivity carriers for pretargeted radioimmunotherapy with favorable pharmacokinetic parameters...
- Combined modality radioimmunotherapy for human prostate cancer xenografts with taxanes and 90yttrium-DOTA-peptide-ChL6ROBERT T O'DONNELL
Department of Internal Medicine, Division of Hematology and Oncology, Section of Radiodiagnosis and Therapy, University of California Davis Medical Center, Sacramento, California 95816, USA
Prostate 50:27-37. 2002..55 MBq;150 microCi) has resulted in durable responses. To make radioimmunotherapy (RIT) more effective, the radiation-enhancing drugs Taxol (paclitaxel) and Taxotere (docetaxel) were tested ..
- Pretargeted radioimmunotherapy for B-cell lymphomasDamian J Green
Clinical Research Division, Fred Hutchinson Cancer Research Center, Department of Medicine, University of Washington, Seattle, Washington 98109, USA
Clin Cancer Res 13:5598s-5603s. 2007..We have investigated the potential utility of pretargeted radioimmunotherapy using monoclonal antibody-streptavidin, immunoconjugates, and fusion proteins in combination with N-..
- Comparison between radioimmunotherapy and external beam radiation therapy for patients with hepatocellular carcinomaZhao Chong Zeng
Department of Radiation Oncology, Zhongshan Hospital, Fudan University, 136 Yi Xue Yuan Road, Shanghai, 200032, P R China
Eur J Nucl Med Mol Imaging 29:1657-68. 2002It has previously been observed in animal studies that, at equivalent doses, radioimmunotherapy (RIT) is 2.5 times more effective than multiple fractions of external beam radiation therapy (EBRT) in inhibiting tumour growth...
- The radiation biology of radioimmunotherapyK L Dixon
Department of Physics, The University of British Colombia, Canada
Nucl Med Commun 24:951-7. 2003The treatment of cancer is a wide and varied field, encompassing many methods and modalities. Radioimmunotherapy is a technique which utilizes the ablative properties of radiation by delivering radioactive particles directly to the tumour ..
- Consensus conference: implementing treatment recommendations on yttrium-90 immunotherapy in clinical practice - report of a European workshopPier Luigi Zinzani
Institute of Hematology and Oncology Seragnoli, Via Massarenti 9, 40138 Bologna, Italy
Eur J Cancer 44:366-73. 2008..This approach would maximise the therapeutic potential of this agent by encouraging its use early in the disease course of follicular lymphomas...
- High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human Carol M Richman
University of California Davis, Sacramento, California 95817, USA
Clin Cancer Res 11:5920-7. 2005Although radioimmunotherapy alone is effective in lymphoma, its application to solid tumors will likely require a combined modality approach...
- Radioimmunotherapy with (111)In/(90)Y-2IT-BAD-m170 for metastatic prostate cancerR T O'Donnell
Department of Internal Medicine, Division of Hematology and Oncology, University of California Davis Medical Center, Sacramento, California 95816
Clin Cancer Res 7:1561-8. 2001..b>Radioimmunotherapy (RIT) uses a tumor-specific monoclonal antibody to deliver systemic, targeted radiation to cancer...
- Feasibility of radioimmunotherapy of experimental pneumococcal infectionE Dadachova
Department of Nuclear Medicine, Albert Einstein College of Medicine, Bronx, New York 10461, USA
Antimicrob Agents Chemother 48:1624-9. 2004..We have recently established that radioimmunotherapy (RIT) can be used to treat experimental fungal infections in mice...
- Targeting radioimmunotherapy of hepatocellular carcinoma with iodine (131I) metuximab injection: clinical phase I/II trialsZhi-Nan Chen
Cell Engineering Research Centre and Department of Cell Biology, State Key Laboratory of Cancer Biology, Fourth Military Medical University, Xi'an, China
Int J Radiat Oncol Biol Phys 65:435-44. 2006..0001 or p = 0.0019). CONCLUSION: Iodine (131I) metuximab injection is safe and active for HCC patients...
- Combining radioimmunotherapy with antihypoxia therapy 2-deoxy-D-glucose results in reduction of therapeutic efficacyJason L J Dearling
Cancer Research UK Targeting and Imaging Group, Department of Oncology, Royal Free and University College Medical School, University College London, London, UK
Clin Cancer Res 13:1903-10. 2007The efficacy of solid tumor radioimmunotherapy is reduced by heterogeneous tumor distribution of the radionuclide, with dose mainly deposited in the normoxic region and by the relative radioresistance of hypoxic tumor cells...
- Comparison of anti-CD20 and anti-CD45 antibodies for conventional and pretargeted radioimmunotherapy of B-cell lymphomasJohn M Pagel
Fred Hutchinson Cancer Research Center and the Department of Medicine, University of Washington, Seattle 98109, USA
Blood 101:2340-8. 2003..These lymphoma xenograft data suggest that pretargeted radioimmunotherapy using either anti-CD20 or anti-CD45 conjugates is highly effective and minimally toxic.
- Editorial: what ails solid tumor radioimmunotherapy?Chaitanya Divgi
Cancer Biother Radiopharm 21:81-4. 2006
- Interaction of radiolabeled antibodies with fungal cells and components of the immune system in vitro and during radioimmunotherapy for experimental fungal infectionEkaterina Dadachova
Department of Nuclear Medicine, Albert Einstein College of Medicine, Bronx, New York 10461, USA
J Infect Dis 193:1427-36. 2006The usefulness of radioimmunotherapy (RIT) for infectious diseases was recently demonstrated for several fungal and bacterial infections, but the mechanisms by which RIT is effective against microbes are uncertain.
- A genetically engineered anti-CD45 single-chain antibody-streptavidin fusion protein for pretargeted radioimmunotherapy of hematologic malignanciesYukang Lin
The Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, 1100 Fairview Avenue North, Seattle, WA 98109, USA
Cancer Res 66:3884-92. 2006..We now show the superiority of pretargeted radioimmunotherapy (PRIT) compared with conventional radioimmunotherapy using a recombinant tetravalent single-chain Ab-..
- Beta-irradiation used for systemic radioimmunotherapy induces apoptosis and activates apoptosis pathways in leukaemia cellsClaudia Friesen
University Children's Hospital, Prittwitzstrasse 43, 89075 Ulm, Germany
Eur J Nucl Med Mol Imaging 30:1251-61. 2003Beta-irradiation used for systemic radioimmunotherapy (RIT) is a promising treatment approach for high-risk leukaemia and lymphoma...
- Copper-67 radioimmunotherapy and growth inhibition by anti-L1-cell adhesion molecule monoclonal antibodies in a therapy model of ovarian cancer metastasisKarin Knogler
Center for Radiopharmaceutical Science, ETH PSI USZ, Paul Scherrer Institute, CH 5232 Villigen, Switzerland
Clin Cancer Res 13:603-11. 2007..We examined the tumor-targeting and therapeutic effects of (67)Cu-labeled single amino acid mutant forms of anti-L1 monoclonal antibody chCE7 in nude mice with orthotopically implanted SKOV3ip human ovarian carcinoma cells...
- Rationales, evidence, and design considerations for fractionated radioimmunotherapyGerald L DeNardo
Department of Internal Medicine, Division of Hematology and Oncology, Section of Radiodiagnosis and Therapy, University of California, Davis Medical Center, Sacramento, California 95816, USA
Cancer 94:1332-48. 2002..used in the broader context of administration of multiple, rather than single, doses of radionuclide for radioimmunotherapy (RIT) or other targeted radionuclide therapies...
- Model prediction of treatment planning for dose-fractionated radioimmunotherapySui Shen
Department of Radiation Oncology, University of Alabama at Birmingham, 35294, USA
Cancer 94:1264-9. 2002Clinical trials of radioimmunotherapy (RIT) often use dose fractionation to reduce marrow toxicity. The dosing scheme can be optimized if marrow and tumor cell kinetics following radiation exposure are known.
- Radioimmunotherapy of prostate cancer using 90Y- and 177Lu-labeled J591 monoclonal antibodies: effect of multiple treatments on myelotoxicityShankar Vallabhajosula
Department of Radiology, Division of Nuclear Medicine, New York Presbyterian Hospital, Weill Medical College of Cornell University, New York 10021, USA
Clin Cancer Res 11:7195s-7200s. 2005Bone marrow is the dose-limiting organ in radioimmunotherapy. Fractionated dose regimens may decrease myelotoxicity and increase greater total administered dose...
- Engineered single chain antibody fragments for radioimmunotherapyA Huhalov
Cancer Research UK Imaging and Targeting Group, Department of Oncology, Royal Free and University College Medical School, Royal Free Campus London, United Kingdom
Q J Nucl Med Mol Imaging 48:279-88. 2004An ideal molecule to deliver radioimmunotherapy (RIT) would be target specific and have prolonged residence time at high concentrations in the tumour with rapid clearance from normal tissues. It would also be non-immunogenic...
- The influence of proteasome inhibitor MG132, external radiation, and unlabeled antibody on the tumor uptake and biodistribution of (188)re-labeled anti-E6 C1P5 antibody in cervical cancer in miceRébécca Phaeton
Department of Obstetrics and Gynecology and Women s Health, Division of Gynecologic Oncology, Albert Einstein College of Medicine, Albert Einstein Cancer Center, Bronx, NY 10461, USA
Cancer 116:1067-74. 2010..The authors of this report recently demonstrated the efficacy of radioimmunotherapy (RIT) targeting viral oncoprotein E6 in the treatment of experimental cervical cancer...
- A phase I trial of radioimmunotherapy with 131I-A5B7 anti-CEA antibody in combination with combretastatin-A4-phosphate in advanced gastrointestinal carcinomasTim Meyer
UCL Cancer Institute, University College London, United Kingdom
Clin Cancer Res 15:4484-92. 2009In preclinical models, radioimmunotherapy with (131)I-A5B7 anti-carcinoembryonic antigen (CEA) antibody ((131)I-A5B7) combined with the vascular disruptive agent combretastatin-A4-phosphate (CA4P) produced cures unlike either agent alone...
- A pharmacokinetic model for radioimmunotherapy delivered through cerebrospinal fluid for the treatment of leptomeningeal metastasesYonggang Lv
Department of Biomedical Engineering, The City College of New York, New York, New York 10031, USA
J Nucl Med 50:1324-31. 2009b>Radioimmunotherapy can effectively treat leptomeningeal metastases when radiolabeled antibodies are administered into the cerebrospinal fluid (CSF)...
- Retargeting interleukin 13 for radioimmunodetection and radioimmunotherapy of human high-grade gliomasW Debinski
Department of Surgery, Pennsylvania State University, College of Medicine, Hershey 17033 0850, USA
Clin Cancer Res 5:3143s-3147s. 1999....
- PET/CT Imaging and Radioimmunotherapy of Prostate CancerKirsten Bouchelouche
PET and Cyclotron Unit, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, Copenhagen, Denmark
Semin Nucl Med 41:29-44. 2011..Prostate cancer represents an attractive target for radioimmunotherapy (RIT) for several reasons, including pattern of metastatic spread (lymph nodes and bone marrow, sites with ..
- Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancerScott T Tagawa
Division of Hematology and Medical Oncology, Weill Cornell Medical College, New York, NY, USA
Cancer 116:1075-83. 2010..Future studies will include approaches to optimize patient selection and incorporate novel strategies to improve the success of anti-PSMA radioimmunotherapy.
- Radioimmunotherapy with an antibody to the HPV16 E6 oncoprotein is effective in an experimental cervical tumor expressing low levels of E6Rébécca Phaeton
Department of Obstetrics and Gynecology and Women s Health, Albert Einstein College of Medicine, Albert Einstein Cancer Center, Bronx, NY, USA
Cancer Biol Ther 10:1041-7. 2010..b>Radioimmunotherapy employs systemically administered radiolabeled monoclonal antibodies (mAbs) that bind to tumor-associated ..
- FDG-PET in the assessment of patients with follicular lymphoma treated by ibritumomab tiuxetan Y 90: multicentric studyE Lopci
Nuclear Medicine Department, University Hospital S Orsola Malpighi, Bologna, Italy
Ann Oncol 21:1877-83. 2010..is the 2-[fluorine-18]fluoro-2-deoxy-D-glucose (FDG)-positron emission tomography (PET) evaluation following radioimmunotherapy (RIT) with ibritumomab tiuxetan Y 90 in patients with non-Hodgkin's follicular lymphoma (FL)...
- Radioimmunotherapy is more effective than antifungal treatment in experimental cryptococcal infectionRuth A Bryan
Department of Nuclear Medicine, Albert Einstein College of Medicine, Bronx, New York 10461, USA
J Infect Dis 202:633-7. 2010b>Radioimmunotherapy (RIT) prolongs the survival of mice infected with Cryptococcus neoformans. To compare the efficacy of RIT with that of amphotericin B, we infected AJ/Cr mice intravenously with either nonmelanized or melanized C...
- Bio-effect model applied to 131I radioimmunotherapy of refractory non-Hodgkin's lymphomaPeter L Roberson
Department of Radiation Oncology, University of Michigan, 519 W William St, Argus I, Ann Arbor, MI 48103 4943, USA
Eur J Nucl Med Mol Imaging 38:874-83. 2011..Treatment with tositumomab and (131)I-tositumomab anti-CD20 radioimmunotherapy (BEXXAR) yields a cold antibody antitumor response (cold protein effect) and a radiation response...
- Chemotherapy synergizes with radioimmunotherapy targeting La autoantigen in tumorsFares Al-Ejeh
Experimental Therapeutics Laboratory, Hanson Institute, Adelaide, South Australia, Australia
PLoS ONE 4:e4630. 2009..inefficient delivery of therapeutic doses of radionuclides to solid tumors limits the clinical utility of radioimmunotherapy. We aim to test the therapeutic utility of Yttrium-90 ((90)Y)-radio-conjugates of a monoclonal antibody, ..
- Radioimmunotherapy is effective against high-inoculum Cryptococcus neoformans infection in mice and does not select for radiation-resistant cryptococcal cellsRuth A Bryan
Departments of Nuclear Medicine, Albert Einstein College of Medicine, Bronx, New York 10461, USA
Antimicrob Agents Chemother 53:1679-82. 2009We investigated the utility of radioimmunotherapy (RIT) in the treatment of experimental cryptococcal infection with high-inoculum and the possibility of RIT treatment selecting for fungal cells with radiation-resistant phenotypes...
- Production and characterization of 188Re-C595 antibody for radioimmunotherapy of transitional cell bladder cancerA Murray
Department of Medical Physics, Medical School, Queen's Medical Centre, Nottingham, United Kingdom
J Nucl Med 42:726-32. 2001..MUC1 mucin is overexpressed on bladder tumors and represents a useful target for radioimmunoscintigraphy and radioimmunotherapy. We report on the production and initial tracer studies of a 188Re-antibody complex directed against this ..
- Susceptibility of the human pathogenic fungi Cryptococcus neoformans and Histoplasma capsulatum to gamma-radiation versus radioimmunotherapy with alpha- and beta-emitting radioisotopesEkaterina Dadachova
Department of Nuclear Medicine, Albert Einstein College of Medicine, 1695A Eastchester Road, Bronx, NY 10461, USA
J Nucl Med 45:313-20. 2004..One novel strategy is to use radioimmunotherapy (RIT) with fungal-binding monoclonal antibodies (mAbs) labeled with radionuclides...
- Evaluation of acute hematologic and long-term pulmonary toxicities of radioimmunotherapy of Cryptococcus neoformans infection in murine modelsE Dadachova
Department of Nuclear Medicine, Albert Einstein College of Medicine, Bronx, NY 10461, USA
Antimicrob Agents Chemother 48:1004-6. 2004We evaluated acute hematological and long-term pulmonary toxicity of radioimmunotherapy in murine models of Cryptococcus neoformans infection...
- Intratumoral distribution of two consecutive injections of chimeric antibody G250 in primary renal cell carcinoma: implications for fractionated dose radioimmunotherapyM G Steffens
Department of Urology, University Hospital Nijmegen, The Netherlands
Cancer Res 59:1615-9. 1999..the intratumoral distribution of the antibody is highly heterogeneous, which may limit the efficacy of radioimmunotherapy. A number of highly dynamic physiological factors have been postulated that may contribute to heterogeneous ..
- Direct radiolabeling of monoclonal antibodies with rhenium-188 for radioimmunotherapy of solid tumors--a review of radiolabeling characteristics, quality control and in vitro stability studiesN Iznaga-Escobar
Center of Molecular Immunology, Havana, Cuba
Appl Radiat Isot 54:399-406. 2001..characteristics, methods for quality control of radioimmunoconjugates and in vitro stability for radioimmunotherapy of solid tumors...
- Pretargeted alpha emitting radioimmunotherapy using (213)Bi 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid-biotinZhengsheng Yao
Department of Nuclear Medicine, Warren G. Magnuson Clinical Center, NIH, Bethesda, Maryland 20892, USA
Clin Cancer Res 10:3137-46. 2004PURPOSE: The use of an alpha emitter for radioimmunotherapy has potential advantages compared with beta emitters...
- Targeted radioimmunotherapy for leptomeningeal cancer using (131)I-3F8K Kramer
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Med Pediatr Oncol 35:716-8. 2000..Intrathecal antibody-based targeted therapies may have clinical potential for patients with leptomeningeal (LM) cancer...
- Phase II study of induction chemotherapy with TPF followed by radioimmunotherapy with Cetuximab and intensity-modulated radiotherapy (IMRT) in combination with a carbon ion boost for locally advanced tumours of the oro-, hypopharynx and larynx--TPF-C-HITAlexandra D Jensen
Dept of Radiation, Oncology INF, Heidelberg Germany
BMC Cancer 11:182. 2011..Combined radioimmunotherapy with cetuximab as well as modern radiotherapy techniques such as intensity-modulated radiotherapy (IMRT) and ..
- Integrin alphavbeta3-targeted radioimmunotherapy of glioblastoma multiformeAnand Veeravagu
Molecular Imaging Program at Stanford, Department of Radiology and Bio X Program, Stanford University School of Medicine, Stanford, California 94305 5484, USA
Clin Cancer Res 14:7330-9. 2008..The purpose of this study was to evaluate the efficacy of a novel 90Y-Abegrin radioimmunotherapeutic agent in murine xenograft glioblastoma models with noninvasive in vivo molecular imaging modalities...
- Results of a national consensus workshop: therapeutic algorithm in patients with follicular lymphoma--role of radioimmunotherapyM Dreyling
Department of Medicine III, Grosshadern, Ludwig Maximilians University, Munich, Germany
Ann Hematol 86:81-7. 2007b>Radioimmunotherapy (RIT) was approved for the treatment of relapsed or refractory CD20-positive follicular lymphoma (FL), subsequent to rituximab containing primary therapy...
- A comparison of the biodistribution and biokinetics of (99m)Tc-anti-CD66 mAb BW 250/183 and (99m)Tc-anti-CD45 mAb YTH 24.5 with regard to suitability for myeloablative radioimmunotherapyInga Buchmann
Department of Nuclear Medicine, University Hospital, Ulm, Germany
Eur J Nucl Med Mol Imaging 30:667-73. 2003b>Radioimmunotherapy (RIT) with radiolabelled monoclonal antibodies (mAbs) is an effective method of achieving myeloablation in leukaemia patients prior to stem cell transplantation (SCT)...
- Antibodies as delivery vehicles for radioimmunotherapy of infectious diseasesEkaterina Dadachova
Department of Nuclear Medicine, Albert Einstein College of Medicine of Yeshiva University, Bronx, NY 10461, USA
Expert Opin Drug Deliv 2:1075-84. 2005..b>Radioimmunotherapy (RIT), a therapeutic modality originally developed for cancer treatment, has recently been suggested as a ..
- Copper-67 as a therapeutic nuclide for radioimmunotherapyIlse Novak-Hofer
Center for Radiopharmaceutical Science ETH-PSI-USZ, Paul Scherrer Institute, CH-5232 Villigen, Switzerland
Eur J Nucl Med Mol Imaging 29:821-30. 2002The application of the beta particle-emitting nuclide 67Cu in radioimmunotherapy is reviewed. The production of the nuclide is outlined, and different production modes are discussed with an emphasis on cyclotron production...
- Pretargeting CD45 enhances the selective delivery of radiation to hematolymphoid tissues in nonhuman primatesDamian J Green
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
Blood 114:1226-35. 2009Pretargeted radioimmunotherapy (PRIT) is designed to enhance the directed delivery of radionuclides to malignant cells...
- Psychological distress of patients undergoing intensified conditioning with radioimmunotherapy prior to allogeneic stem cell transplantationN Grulke
University Clinic for Psychosomatic Medicine and Psychotherapy, Frauensteige 14a, D 89075 Ulm, Germany
Bone Marrow Transplant 35:1107-11. 2005..is a pilot study comparing the emotional distress of patients receiving an intensified conditioning regimen (radioimmunotherapy=RIT) with patients receiving conventional conditioning for allogeneic stem cell transplantation...
- (124)I-L19-SIP for immuno-PET imaging of tumour vasculature and guidance of (131)I-L19-SIP radioimmunotherapyBernard M Tijink
Department of Otolaryngology Head and Neck Surgery, VU University Medical Center, De Boelelaan 1117, P O Box 7057, 1007 MB, Amsterdam, The Netherlands
Eur J Nucl Med Mol Imaging 36:1235-44. 2009..A clinical radioimmunotherapy (RIT) trial with (131)I-L19-SIP was recently started...
- A phase I trial of (90)Y-DOTA-anti-CEA chimeric T84.66 (cT84.66) radioimmunotherapy in patients with metastatic CEA-producing malignanciesJeffrey Y C Wong
City of Hope National Medical Center and Beckman Research Institute, Duarte, CA 91010, USA
Cancer Biother Radiopharm 21:88-100. 2006Previous radioimmunotherapy (RIT) clinical trials at this institution with (90)Y-labeled cT84.66 anti-CEA (carcinoembryonic antigen) evaluated the antibody conjugated to diethylenetriaminepentaacetic acid (DTPA)...
- Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomabMark S Kaminski
University of Michigan Comprehensive Cancer Center, Ann Arbor, USA
J Clin Oncol 23:7985-93. 2005..To study efficacy and safety of re-treatment with I-131 tositumomab in patients with low-grade, follicular, or transformed low-grade B-cell lymphoma who relapsed following a response to I-131 tositumomab...
- Radioimmunotherapy for non-Hodgkin's lymphomaChristos Emmanouilides
UCLA Medical Center, Los Angeles, CA 90095, USA
Semin Oncol 30:531-44. 2003b>Radioimmunotherapy (RIT) treatment for lymphoma is a novel targeted therapeutic approach...
- Cancer stem cell targeting using the alpha-particle emitter, 213Bi: mathematical modeling and feasibility analysisGeorge Sgouros
Division of Nuclear Medicine, Russell H Morgan Department of Radiology and Radiological Science, Johns Hopkins University, School of Medicine, Baltimore, MD 21231, USA
Cancer Biother Radiopharm 23:74-81. 2008....
- Fractionated radioimmunotherapy of intraperitoneally growing ovarian cancer in nude mice with 211At-MX35 F(ab')2: therapeutic efficacy and myelotoxicityJörgen Elgqvist
Department of Radiation Physics, The Sahlgrenska Academy at Goteborg University, SE 413 45 Goteborg, Sweden
Nucl Med Biol 33:1065-72. 2006The aim of this study was to investigate the therapeutic efficacy and myelotoxicity during fractionated radioimmunotherapy of ovarian cancer in mice...
- Commentary: let the tail wag the dog: the case for radioimmunotherapy of low-grade follicular lymphomaJohn P Plastaras
Department of Radiation Oncology, Hospital of the University of Pennsylvania, 2 Donner Building, 3400 Spruce Street, Philadelphia, PA 19104, USA
Oncologist 13:655-6. 2008
- Whole-body clearance kinetics and external dosimetry of 131I-3F8 monoclonal antibody for radioimmunotherapy of neuroblastomaLawrence T Dauer
Department of Medical Physics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
Health Phys 92:33-9. 2007....
- Single-cell dosimetry for radioimmunotherapy of B-cell lymphoma patients with special reference to leukemic spreadCecilia Hindorf
Joint Department of Physics, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom
Cancer Biother Radiopharm 22:357-66. 2007..Treatment efficacy could, therefore, depend on the radionuclide used. The aim of this study was to investigate dosimetry at a cellular level for three isotopes of radioiodine...
- Therapeutic efficacy of 177Lu-CHX-A''-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapyMarcus P Kelly
Tumour Targeting Laboratory, Ludwig Institute for Cancer Research, Melbourne Centre for ClinicalSciences, Austin Hospital, Heidelberg, Victoria, Australia
Prostate 69:92-104. 2009..and therapeutic efficacy of Lutetium-177 (177Lu) radiolabeled anti-Lewis Y monoclonal antibody hu3S193 radioimmunotherapy (RIT) in mice bearing prostate cancer xenografts...
- Practical considerations and radiation safety in radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin)Leo I Gordon
Division of Hematology/Oncology, Feinberg School of Medicine, and the Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL 60611, USA
Semin Oncol 30:23-8. 2003..This treatment regimen requires a coordinated multidisciplinary approach. Oncologists play a leading role in selecting patients for (90)Y ibritumomab tiuxetan therapy and in prescribing and overseeing the treatment...
- Yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin) induces long-term durable responses in patients with relapsed or refractory B-Cell non-Hodgkin's lymphomaGregory A Wiseman
Mayo Clinic, Rochester, MN, USA
Cancer Biother Radiopharm 20:185-8. 2005Yttrium-90 ((90)Y) ibritumomab tiuxetan (Zevalin) radioimmunotherapy is an effective treatment for relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL), with overall response rates ranging from 74% to 82%...
- New developments in immunotherapy for non-Hodgkin's lymphomaJohn P Leonard
Center for Lymphoma and Myeloma, Division of Hematology and Medical Oncology, Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, NY 10021, USA
Curr Oncol Rep 7:364-71. 2005..Further studies of unlabeled and radiolabeled immunotherapies are ongoing in order to optimize their use for maximal clinical benefit...
- 90Y-ibritumomab tiuxetan: rationale for patient selection in the treatment of indolent non-Hodgkin's lymphomaAntonio J Grillo-Lopez
Neoplastic and Autoimmune Diseases Research Institute, Rancho Santa Fe, CA 92067 3797, USA
Semin Oncol 32:S44-9. 2005b>Radioimmunotherapy with 90Y-ibritumomab tiuxetan (Zevalin; Biogen Idec Inc, San Diego, CA, and Schering AG, Berlin, Germany) was approved in the United States in 2002 for patients with relapsed or refractory, low-grade, follicular, or ..
- Use of 90Y-ibritumomab tiuxetan in non-Hodgkin's lymphomaRobert Marcus
Addenbrooke's Hospital, Cambridge, UK
Semin Oncol 32:S36-43. 2005..Thus, there is a continuing need for novel therapeutic options. One such strategy is targeted radioimmunotherapy, which is an attractive approach because lymphoma cells are inherently sensitive to radiation...
- Development of 131I-tositumomabValerie Lewington
Royal Marsden Hospital, Sutton, UK
Semin Oncol 32:S50-6. 2005..Targeted treatment using radioimmunotherapy (RIT), radiolabeled monoclonal antibodies directed against tumor-specific antigens, is an attractive option ..
- Radioimmunotherapy of non-Hodgkin's lymphoma revisitedDavid M Goldenberg
J Nucl Med 46:383-4. 2005
- Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 AbAjay K Gopal
Department of Medicine, Division of Medical Oncology, University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA 98195, USA
Blood 112:830-5. 2008..showed that rituximab pretreatment significantly reduced B-NHL targeting and tumor control by CD20-directed radioimmunotherapy (RIT), but had no impact on targeting CD45...
- Radiobiology of radioimmunotherapy: targeting CD20 B-cell antigen in non-Hodgkin's lymphomaM Carmen Hernandez
Department of Radiation Oncology, Stanford University Medical Center, 269 Campus Drive West, Stanford, CA 94305, USA
Int J Radiat Oncol Biol Phys 59:1274-87. 2004The radiobiology of radioimmunotherapy is an important determinant of both the toxicity and the efficacy associated with the treatment of B-cell non-Hodgkin's lymphoma with radiolabeled anti-CD20 monoclonal antibodies...
- Bias reduction in correlation of radiation-absorbed dose with responseKenneth F Koral
J Nucl Med 45:1271; author reply 1271-2. 2004
- Biodistribution and therapeutic efficacy of (125/131)I-, (186)Re-, (88/90)Y-, or (177)Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal originManuel J Koppe
Department of Surgery, University Medical Center Nijmegen, Nijmegen, The Netherlands
J Nucl Med 45:1224-32. 2004Therapeutic efficacy in radioimmunotherapy depends, among other things, on the choice of the radionuclide...
- Relative biologic effects of low-dose-rate alpha-emitting 227Th-rituximab and beta-emitting 90Y-tiuexetan-ibritumomab versus external beam X-radiationJostein Dahle
Department of Radiation Biology, The Norwegian Radium Hospital, Montebello, Oslo, Norway
Int J Radiat Oncol Biol Phys 72:186-92. 2008..To determine the relative biologic effects (RBE) of alpha-particle radiation from 227Th-rituximab and of beta-radiation from 90Y-tiuexetan-ibritumomab (Zevalin) compared with external beam X-radiation in the Raji lymphoma xenograft model...
- Radioimmunotherapy: a new treatment modality for B-cell non-Hodgkin's lymphomaIrene Ghobrial
Mayo College of Medicine, Rochester, Minnesota 55905, USA
Oncology (Williston Park) 18:623-30; discussion 633-4, 637-8, 640. 2004The field of radioimmunotherapy for the treatment of non-Hodgkin's lymphoma (NHL) has advanced significantly over the past decade, and several radioimmunoconjugates are being tested in clinical trials...
- Does health economics have an impact on non-Hodgkin's lymphoma patients' options?Andreas Otte
Nucl Med Commun 29:748-9. 2008
- [Nuclear medicine and lymphoma]Alberto Fernández de Sevilla Ribosa
Rev Esp Med Nucl 25:77-9. 2006
- A novel platform for radioimmunotherapy: extracorporeal depletion of biotinylated and 90Y-labeled rituximab in patients with refractory B-cell lymphomaOla Linden
Department of Oncology, Lund University Hospital, Lund, Sweden
Cancer Biother Radiopharm 20:457-66. 2005b>Radioimmunotherapy is limited by the absorbed dose to radiosensitive organs...
- Radioimmunotherapy for Non-Hodgkin's LymphomaArati V Rao
Division of Medical Oncology and Division of Geriatrics, Duke University Medical Center and Durham Veterans Affairs Medical Center, Durham, NC 27710, USA
Clin Med Res 3:157-65. 2005..e., radioimmunotherapy (RIT) in patients with NHL...
- Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphomaChristos Emmanouilides
Division of Hematology and Oncology, University of California Los Angeles, Los Angeles, CA 90095 1678, USA
Leuk Lymphoma 47:629-36. 2006..The quality of disease remissions obtained when (90)Y ibritumomab tiuxetan is administered after first relapse appears to be comparable with that observed with most chemotherapy regimens in first-relapse patients...
- Targeted cancer therapy with a novel low-dose rate alpha-emitting radioimmunoconjugateJostein Dahle
Department of Radiation Biology, Norwegian Radium Hospital, Oslo, Norway
Blood 110:2049-56. 2007..A particularly interesting approach is in radioimmunotherapy. However, alpha-emitting antibody conjugates have been difficult to exploit clinically due to the short half-..
- [Radioimmunotherapy for B-cell lymphoma]Kensei Tobinai
Rinsho Ketsueki 47:463-70. 2006
- Clinical development of radioimmunotherapy for B-cell non-Hodgkin's lymphomaRuby F Meredith
Department of Radiation Oncology, University of Alabama Medical Center, Birmingham, AL, USA
Int J Radiat Oncol Biol Phys 66:S15-22. 2006..Two radioimmunotherapy agents that target the CD20 antigen, (131)I-tositumomab and (90)Y-ibritumomab tiuxetan, have been approved ..
- Enhanced efficacy of 90Y-radiolabeled anti-Lewis Y humanized monoclonal antibody hu3S193 and paclitaxel combined-modality radioimmunotherapy in a breast cancer modelMarcus P Kelly
Tumour Targeting Program, Ludwig Institute for Cancer Research, Austin Hospital, Heidelberg, Victoria 3084, Australia
J Nucl Med 47:716-25. 2006b>Radioimmunotherapy (RIT) of solid tumor is often limited in efficacy because of restrictions in achieved tumor dose...
- Cure of incurable lymphomaGerald L DeNardo
Radiodiagnosis and Therapy, Division of Hematology Oncology, University of California Davis Medical Center, Sacramento, CA, USA
Int J Radiat Oncol Biol Phys 66:S46-56. 2006..antibody (MAb) treatment is to conjugate radionuclides to the MAb to deliver systemic radiotherapy (radioimmunotherapy; RIT). The antigen, MAb, and its epitope can make a difference in the performance of the drug...
- [Radioimmunotherapy with 90Y-ibritumomab tiuxetan in lymphomas]X Setoain
Medicina Nuclear, , Barcelona
Rev Esp Med Nucl 25:55-68; quiz 69-70.. 2006
- [Radioimmunotherapy for non-Hodgkin lymphoma: historical development and current status]C Emmanouilides
Division Haematology-Oncology, UCLA, Los Angeles, USA
Rev Esp Med Nucl 25:42-54. 2006b>Radioimmunotherapy treatment for lymphoma is a novel targeted therapeutic approach...
- Intraperitoneal pretarget radioimmunotherapy with CC49 fusion proteinDonald J Buchsbaum
Department of Radiation Oncology, University of Alabama at Birmingham, Alabama 35294 6832, USA
Clin Cancer Res 11:8180-5. 2005This study examined a pretarget radioimmunotherapy strategy for treatment of an i.p. tumor model (LS174T).
- Current results and future applications of radioimmunotherapy management of non-Hodgkin's lymphomaEdgardo S Santos
Tulane Cancer Center, Tulane University Health Sciences Center, New Orleans, LA, USA
Leuk Lymphoma 47:2453-76. 2006....
- [Radioimmunotherapy in non-Hodgkin's lymphoma. With focus on anti-CD20 treatment]Peter de Nully Brown
H S Rigshospitalet, Finsencenteret, Haematologisk Afdeling L 4042, og Universitetssjukhuset i Lund, Onkologisk Klinik, Sverige
Ugeskr Laeger 167:3867-9. 2005b>Radioimmunotherapy in indolent NHL is a new and promising therapy which adds a new therapeutic tool to the treatment palette. Recent advantages in RIT are described and perspectives discussed.
- [New trends in non-Hodgkin's lymphoma therapy]Grzegorz Mazur
Katedra i Klinika Hematologii, Nowotworów Krwi i Transplantacji Szpiku Akademii Medycznej we Wrocławiu
Postepy Hig Med Dosw (Online) 60:707-21. 2006..Apart from monoclonal antibodies, radioimmunotherapy, and autologous stem cell transplantation, which are used as standard therapy for some lymphomas, new drugs ..
- Dose-attenuated radioimmunotherapy with tositumomab and iodine 131 tositumomab in patients with recurrent non-Hodgkin's lymphoma (NHL) and extensive bone marrow involvementJodi V Mones
Center for Lymphoma and Myeloma, Division of Hematology Oncology, Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, NY 10021, USA
Leuk Lymphoma 48:342-8. 2007b>Radioimmunotherapy (RIT) with tositumomab and iodine 131 tositumomab can produce durable and complete responses in relapsed/refractory low-grade Non-Hodgkin's lymphoma...
- Radioimmunotherapy as a therapeutic option for Non-Hodgkin's lymphomaRoger M Macklis
Cleveland Clinic Lerner College of Medicine and Department of Radiation Oncology, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
Semin Radiat Oncol 17:176-83. 2007b>Radioimmunotherapy (RIT) represents a relatively new antibody-based radiopharmaceutical treatment for patients with various kinds of tumors...
- A phase I study of 90yttrium-ibritumomab-tiuxetan in children and adolescents with relapsed/refractory CD20-positive non-Hodgkin's lymphoma: a Children's Oncology Group studyErin Cooney Qualter
Division of Pediatric Heamtology and Blood and Marrow Transplantation, Medicine and Pathology, Columbia University, New York, New York 10032, and Children s Hospital of Philadelphia, PA, USA
Clin Cancer Res 13:5652s-5660s. 2007..There is no data on the safety and feasibility of 90Y-IT in refractory childhood CD20+ lymphoma...
- Enhanced efficacy of radioimmunotherapy with 90Y-CHX-A''-DTPA-hu3S193 by inhibition of epidermal growth factor receptor (EGFR) signaling with EGFR tyrosine kinase inhibitor AG1478Fook T Lee
Tumour Targeting Program, Ludwig Institute for Cancer Research, Austin Hospital, Heidelberg, Victoria, Australia
Clin Cancer Res 11:7080s-7086s. 2005..The effect of EGFR signaling abrogation by EGFR tyrosine kinase inhibitor on the efficacy of radioimmunotherapy has not been reported previously...
- Radiotherapy of CD19 expressing Daudi tumors in nude mice with Yttrium-90-labeled anti-CD19 antibodyDaniel A Vallera
Department of Therapeutic Radiology Radiation Oncology, University of Minnesota Cancer Center, Minneapolis, MN, USA
Cancer Biother Radiopharm 19:11-23. 2004..Because radiolabeled anti-CD19 antibody can be used to deliver radiation selectively to lymphohematopoietic tissue, these data support the use of 90Y anti-CD19 antibodies in treating B-cell malignancies...
- Radiation dosimetry results from a Phase II trial of ibritumomab tiuxetan (Zevalin) radioimmunotherapy for patients with non-Hodgkin's lymphoma and mild thrombocytopeniaGregory A Wiseman
Mayo Clinic, Rochester, MN 55905, USA
Cancer Biother Radiopharm 18:165-78. 2003..These correlations were not consistent across the total patient population, and therefore, could not be exploited to predict hematologic toxicity...
- Radioimmunotherapy with iodine-131 tositumomab in patients with low-grade non-Hodgkin's B-cell lymphoma does not induce loss of acquired humoral immunity against common antigensT Nordøy
Department of Oncology, University Hospital of Tromsø, Tromsø, N 9038, Norway
Clin Immunol 100:40-8. 2001..No significant reduction in antibody concentrations to tetanus or measles could be detected. The data show that acquired humoral immunity against common antigens appears to be preserved despite a temporary loss of B-lymphocytes...
- Radioimmunotherapy of a human lung cancer xenograft with monoclonal antibody RS7: evaluation of (177)Lu and comparison of its efficacy with that of (90)Y and residualizing (131)IR Stein
Garden State Cancer Center, Belleville NJ 07109, USA
J Nucl Med 42:967-74. 2001..CONCLUSION: (177)Lu-RS7 is an effective radioimmunoconjugate for radioimmunotherapy. With its radiophysical properties similar to those of (131)I, coupled with its facile and stable attachment ..
- Quantitative 89Zr immuno-PET for in vivo scouting of 90Y-labeled monoclonal antibodies in xenograft-bearing nude miceIris Verel
Department of Otolaryngology/Head and Neck Surgery, VU University Medical Center, Amsterdam, The Netherlands
J Nucl Med 44:1663-70. 2003Immuno-PET as a scouting procedure before radioimmunotherapy (RIT) aims at the confirmation of tumor targeting and the accurate estimation of radiation dose delivery to both tumor and normal tissues...
- Radioimmunotherapy of B-cell non-Hodgkin's lymphoma: from clinical trials to clinical practiceMalik E Juweid
Division of Nuclear Medicine, Department of Radiology, University of Iowa Hospitals and Clinics, Iowa City 52242, USA
J Nucl Med 43:1507-29. 2002b>Radioimmunotherapy (RIT) is a new treatment modality for B-cell non-Hodgkin's lymphoma (NHL)...
- Targeted liposomal radiotherapy of malignant mesotheliomaJiang He; Fiscal Year: 2010..Highly selective tumor location and targeting are needed. Our long term goal is to develop effective radioimmunotherapy (RIT) for human cancers by marrying radiotherapy with nanotechnology...
- Bispecific Antibody Engineering for AML RITOLIVER W contact PRESS; Fiscal Year: 2010..of this research proposal is to maximize the cure rate of AML using a novel approach employing pretargeted radioimmunotherapy (PRIT) with genetically engineered bispecific antibodies...
- Foundations of Pretargeted RadioimmunotherapyKARL WITTRUP; Fiscal Year: 2009Delivery of cell-killing doses of ionizing radiation to tumors is the objective of antibody-directed radioimmunotherapy (RIT)...
- CD45 Pretargeted Radioimmunotherapy for AMLOliver W Press; Fiscal Year: 2010..The objective of this research proposal is to improve the cure rate of AML using radioimmunotherapy (RIT) targeting the CD45 cell antigen...
- NEW BCAS FOR RADIOIMMUNOTHERAPY WITH RADIOMETALSDonald Buchsbaum; Fiscal Year: 2001..The experiments described in this application will provide answers to these questions. These studies would establish the rationale for human clinical RIT trials in patients with Jp. cancer using HuCC49ACH2. ..
- NOVEL SEROTHERAPY STRATEGIES--PLASMA CELL MALIGNANCIESSTEVEN TREON; Fiscal Year: 2004..treatment approach for MM and WM patients involves use of antibody mediated immunotherapy (serotherapy) and radioimmunotherapy. As part of our efforts to develop serotherapy for PCD, we have sought to target tumor selective antigens on ..
- Hematopoietic Cell Transplantation for Hematologic MalignanciesStephen Forman; Fiscal Year: 2007..This grant consists of four translational clinical projects and three cores. Project I entitled "Radioimmunotherapy-based Transplant Regimens for Treatment of B-cell Lymphoma and Acute Myelogenous Leukemia" is focused on ..
- PRETARGETED RADIOIMMUNOTHERAPY OF CD20+ LYMPHOMASOliver W Press; Fiscal Year: 2010..The objective of this research proposal is to optimize radioimmunotherapy (RIT) of B cell lymphomas utilizing pretargeting amplification strategies to improve the efficacy and ..
- BIFUNCTIONAL CHELATING AGENTS IN TUMOR LOCALIZATIONClaude Meares; Fiscal Year: 1999..Antibodies have been conjugated to metal chelates for radioimmunotherapy and studied extensively in recent years, and are in clinical trials at various stages...
- TWO COMPARTMENT MODELS TO IMPROVE BRAIN TUMOR THERAPYEdward A Neuwelt; Fiscal Year: 2010..In aim 4 clinical trials of immunotherapy, radioimmunotherapy, and neurotoxicity in PCNSL will be conducted...
- TWO COMPARTMENT MODELS TO IMPROVE BRAIN TUMOR THERAPYEdward Neuwelt; Fiscal Year: 2009..In aim 4 clinical trials of immunotherapy, radioimmunotherapy, and neurotoxicity in PCNSL will be conducted...
- TWO COMPARTMENT MODELS TO IMPROVE BRAIN TUMOR THERAPYEdward Neuwelt; Fiscal Year: 2009..In aim 4 clinical trials of immunotherapy, radioimmunotherapy, and neurotoxicity in PCNSL will be conducted...
- Radioimmunotherapy of Acute LeukemiaEneida Nemecek; Fiscal Year: 2007....
- Foundations of Pretargeted RadioimmunotherapyKARL D WITTRUP; Fiscal Year: 2010Delivery of cell-killing doses of ionizing radiation to tumors is the objective of antibody-directed radioimmunotherapy (RIT)...
- Novel glutamate conjugates for radiotargeting PSMAJohn Babich; Fiscal Year: 2004The development of novel approaches for radioimmunoimaging and radioimmunotherapy is driven by the high incidence and mortality rate associated with prostate cancer in the United States...
- PRETARGETED RADIOIMMUNOTHERAPY OF CD20+ LYMPHOMASOliver Press; Fiscal Year: 2001..pretargeting amplification strategies to improve the efficacy and decrease the toxicity of conventional radioimmunotherapy (RAIT)...
- Improved Tumor Radiotherapy by MORF pretargetingDonald Hnatowich; Fiscal Year: 2005Despite several decades of effort, conventional radioimmunotherapy of hematopoietic and especially solid tumors is still providing marginal results. As such, alternative methods of treating these diseases are needed...